Related Experiment Video
Updated: Mar 22, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.3K
Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and
H A Dowlat1, M K Kuhlmann2, H Khatami3
1PharmaBio Consulting, Freiburg, Germany.
Diabetes, Obesity & Metabolism
|April 22, 2016
Summary
Biosimilars require specific studies to prove interchangeability with reference products. Evolving regulations and limited guidance highlight the need for clear pathways to ensure biosimilar safety and efficacy.
Area of Science:
- Pharmacology
- Regulatory Science
- Biotechnology
Background:
- Biosimilars, complex biological products, face evolving regulatory frameworks lacking global harmonization.
- Ensuring biosimilar safety and efficacy, especially regarding interchangeability, is crucial for clinician and patient confidence.
- Current regulations differ significantly from those for small-molecule generics.
Purpose of the Study:
- To provide an overview of the regulatory landscape for demonstrating biosimilar interchangeability.
- To focus on biosimilar insulin analogues and discuss experiences with other biosimilar products.
- To propose study designs for evaluating interchangeability with biosimilar insulin analogues and discuss clinical implications.
Main Methods:
- Review of current regulatory frameworks for biosimilar interchangeability.
- Analysis of experiences with various biosimilar products.
- Proposal of study designs for biosimilar insulin analogue interchangeability assessments.
Main Results:
- The regulatory framework for biosimilar interchangeability is complex and evolving, with limited specific guidance.
- Demonstrating interchangeability requires stringent studies, particularly for biosimilar insulin analogues.
- Automatic substitution of biosimilars is not widely permitted but may become more common.
Conclusions:
- Clearer regulatory guidance and standardized study designs are needed to establish biosimilar interchangeability.
- Further research is essential to ensure the safety and efficacy of biosimilars, particularly in the context of interchangeability.
- Understanding the implications of interchangeability is vital for clinical practice and patient care.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
348
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
348
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
207
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
207
01:16Bioequivalence Data: Statistical Interpretation
314
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
314
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
358
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
358
01:13Bioequivalence studies: Biowaivers
380
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
380